Clinical Trials Logo

Prostate Hyperplasia clinical trials

View clinical trials related to Prostate Hyperplasia.

Filter by:

NCT ID: NCT06469125 Enrolling by invitation - Clinical trials for Prostate Hyperplasia

Anatomic Endoscopic Prostate Enucleation and BICEP Classification

BICEP
Start date: June 15, 2024
Phase:
Study type: Observational

The Bladder Injury Classification System for Endoscopic Procedure (BICEP) is designed to provide a systematic framework for categorizing bladder injuries that occur during endoscopic procedures. By standardizing the classification of these injuries, BICEP promotes a more consistent approach to diagnosis, management, and prevention across different urologic interventions. This study aims to validate and implement the BICEP system during morcellation. This study will: Validate BICEP by using real-life clinical scenarios to ensure its applicability and effectiveness. Assess the incidence and types of bladder injuries during morcellation, using the BICEP categorization to standardize injury reporting and enhance treatment protocols.

NCT ID: NCT06224218 Recruiting - Clinical trials for Prostate Hyperplasia

Prostate Single Port & Laser Enucleation Comparison Trial

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

Surgical treatments for benign prostatic hyperplasia (BPH) are necessary when non-procedural approaches fail to alleviate lower urinary tract symptoms (LUTS) or bladder outlet obstruction (BOO). Open simple prostatectomy and laser enucleation are recommended for prostatic adenoma size greater than 80 ml. Minimally invasive approaches, such as robotic-assisted simple prostatectomy, have gained popularity due to their comparable outcomes with lower morbidity. The introduction of the da Vinci single-port (SP) robotic platform offers potential advantages, but its outcomes have not been thoroughly investigated. This randomized controlled trial aims to compare the outcomes of SP simple prostatectomy performed using the da Vinci robotic platform versus thulium laser enucleation of the prostate for the treatment of BPH and BOO.

NCT ID: NCT06116851 Recruiting - Prostate Cancer Clinical Trials

Prostate Metabolism, Cancer Risk and Gut Microbiota

PROMIC
Start date: June 1, 2022
Phase:
Study type: Observational

This is a prospective, single center translational multiple cohort study to investigate the association of gut microbiota and prostate cancer.

NCT ID: NCT06038890 Recruiting - Clinical trials for Prostate Hyperplasia

The Learning Curve of Transurethral Holmium Laser Enucleation of the Prostate, Prospective Assessment

Start date: August 1, 2023
Phase: N/A
Study type: Interventional

Despite the high-quality evidence supporting the safety and efficacy of Holmium laser enucleation of the prostate (HOLEP), wide adoption of the procedure is hindered by learning difficulties. Veil-sparing HOLEP was popularized with a standardized approach to learning. Prospective multicenter assessment of the learning curve of HoLEP through a novel technique with structured learning protocol. Learning outcome measures will be assessed against time and number of performed cases of new learners in a multicenter study.

NCT ID: NCT05941260 Completed - Clinical trials for Prostate Hyperplasia

Standardization of Prostatic Resection by Virtual Computational Reconstruction and Computational Flow Dynamics

Start date: July 15, 2023
Phase:
Study type: Observational

The enlargement of the prostate is responsible for voiding dysfunction in men, and especially elderly men. The primary surgical treatment for symptomatic benign prostatic hypertrophy (BPH) was transurethral resection of the prostate (TURP). However, current resection techniques are predominantly experience-based and judgment-based, with little evidence to support the most effective portion of the prostate to be respected. So, the investigators plan through the study to construct a flow diagram to evaluate the amount of tissue needed to be resected to improve voiding flow dynamics.

NCT ID: NCT05531240 Recruiting - Clinical trials for Prostate Hyperplasia

Transurethral Prostate Resection (TURP) vs. Prostate Artery Embolization (PAE)

Start date: October 2022
Phase: N/A
Study type: Interventional

This study focuses on the treatment of benign prostatic hyperplasia which causes lower urinary tract symptoms. The purpose of the research project is to evaluate PAE in terms of both medical and health economic outcomes. To evaluate whether there are any differences in effect (IPSS), complications, costs and perceived quality of life compared with TUR-P.

NCT ID: NCT05443451 Recruiting - Clinical trials for Prostate Hyperplasia

BETTY: BEnign Prostatic Hyperplasia Transperineal Targeted Microwave therapY

Start date: September 8, 2022
Phase: N/A
Study type: Interventional

This is a pilot study on applying 3D-Ultrasound-Guided Transperineal Microwave needle ablation for men with symptomatic benign prostatic hyperplasia (BPH).

NCT ID: NCT05440981 Recruiting - Clinical trials for Prostate Hyperplasia

Implanted Nitinol Device (iTind) System in Chinese Males With Lower Urinary Tract Symptom Secondary to BPH

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

This is a prospective series of consecutive cases of patients undergoing iTind for the treatment of male LUTS.

NCT ID: NCT05108662 Completed - Clinical trials for Prostate Hyperplasia

Inflammatory Markers: HOLEP Versus TURP

Start date: February 1, 2020
Phase: N/A
Study type: Interventional

Aim of the study is to compare the systemic inflammatory markers and surgical stress response in patients undergoing HOLEP or TUR-P surgery.

NCT ID: NCT05059431 Completed - Clinical trials for Prostate Hyperplasia

The Effect of Human Prostate Tissue on Platelet Activation

Start date: February 4, 2015
Phase:
Study type: Observational

Transurethral resection of the prostate (TURP) is a common and standard urological surgical procedure for managing benign prostatic hyperplasia (BPH). Although surgical technology improved in recent decades, severe complications such as TURP syndrome, hematuria, and postoperative hemorrhage were still considerable. Coagulopathy is one of rare but devastating complication which may contribute to bleeding during and after TURP. Although the exact pathophysiological condition of coagulopathy is not clear, there are several possible mechanisms of TURP associated coagulopathy including: urokinase- (u-PA) and tissue-type plasminogen activator (t-PA)-related fibrinolysis; absorption of irrigating fluid associated dilutional coagulopathy; release of prostatic particles rich in tissue thromboplastins into the circulation causing secondary fibrinolysis and disseminated intravascular coagulopathy (DIC); sepsis with DIC associated with bacteria entering the circulation due to prostatic venous sinuses opening and the using of high pressure irrigation. On the other hand, platelet are essential to hemostasis and thrombosis and its activation also contributes to leukocyte recruitment and DIC. Furthermore, previous studies demonstrated that activated platelets could express TLR4, CD40L, P-selectin and induce platelet-leukocyte aggregation (PLA), which were considered important for systemic inflammatory responses and DIC development. Currently, no study investigating the association of prostate particle and platelet activation. Here, we tested the hypothesis that prostate tissue may induce inflammatory responses through platelet activation by measuring the expression of TLR4, CD40L, P-selectin and PLA on platelets.